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Abstract: Background and Objectives: Post-traumatic stress disorder (PTSD) is a common 
psychiatric disorder resulting from a traumatic event, is manifested through hyperarousal, anxiety, 
depressive symptoms, and sleep disturbances. Despite several therapeutic approaches being 
available, both pharmacological and psychological, recently a growing interest has developed in 
using cannabis and synthetic cannabinoids stems from their consideration as more efficient and 
better tolerated alternatives for the treatment of this condition. The present paper aims to evaluate 
the clinical and therapeutic potentials of medical cannabis and synthetic cannabinoids in treating 
PTSD patients. Methods: A systematic electronic search was performed, including all papers 
published up to May 2019, using the following keywords (((cannabis[Title/Abstract]) OR (synthetic 
cannabinoids [Title/Abstract])) AND ((PTSD[Title/Abstract]) OR (Posttraumatic stress 
disorder[Title/Abstract]))) for the topics ‘Cannabis’, ‘Synthetic Cannabinoids’, ‘PTSD’, and MESH 
terms, on the PubMed, Cochrane Library, and Web of Science online databases. For data gathering 
purposes, PRISMA guidelines were followed. Results were organized into two groups, considering 
cannabis and synthetic cannabinoids as different therapeutic approaches for PTSD. Results: Present 
data show that cannabis and synthetic cannabinoids, both acting on the endocannabinoids system, 
may have a potential therapeutic use for improving PTSD symptoms, e.g., reducing anxiety, 
modulating memory-related processes, and improving sleep. Conclusions: Even though the current 
literature suggests that cannabis and synthetic cannabinoids may have a role in the treatment of 
PTSD, there is currently limited evidence regarding their safety and efficacy. Therefore, additional 
research is needed in order to better understand the effectiveness and therapeutic usage of these 
drug classes and monitor their safety.  
Keywords: PTSD; trauma; CBD; cannabis; endocannabinoid system; cannabinoids; synthetic 
cannabinoids 
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1. Introduction 
1.1. Post Traumatic Stress Disorder (PTSD) 
Post-traumatic stress disorder (PTSD) is a psychiatric condition that develops as an aberrant 
adaptation to a traumatic event. The disorder may manifest itself through a broad range of 
symptoms, involving cognition (e.g., repeated recall of the event, through intrusive thoughts, 
flashbacks, nightmares), mood (e.g., depression, anxiety), and emotion (e.g., psychological instability, 
impulsivity, and hyperarousal), and impaired social abilities [1,2], that can cause a significant 
alteration in personal and interpersonal functioning. Thus, the conceptual model of PTSD as a 
disorder of fear conditioning and extinction can assist our understanding of how the underlying 
neurobiological dysfunction observed in subjects suffering from PTSD. Symptoms arise in response 
to an acutely traumatic event, that is an incident that may cause serious injury or is life-threatening 
and is perceived as uncontrollable and dangerous. The effect is an activation of the hypothalamic–
pituitary axis as well as of the locus coeruleus and the noradrenergic system, regions which are 
connected to the amygdala and hippocampus, mediating, respectively, fear conditioning and 
memory consolidation [3]. As a result, the experience, associated sensory stimuli, and emotional 
response (fear) become encoded, such that later exposure to a related cue triggers reactivation of the 
traumatic memories as well as anxiety and increased arousal [3]. Thus, the pathophysiology of PTSD 
involves several neurotransmitters, including the noradrenergic, serotonergic, endogenous 
cannabinoid, and opioid systems, as well as the hypothalamic–pituitary adrenal axis and the release 
of the corticotropin-releasing factor, which are systems involved in other psychiatric conditions, such 
as mood or anxiety disorders [4]. Structural changes and central neurotransmitter imbalances involve 
the following mechanisms: 1) increased responsivity in the amygdala and decreased volume in the 
prefrontal cortex and in the hippocampus, triggering hyperarousal and anxiety; 2) dysfunction in the 
hypothalamic–pituitary axis coordinating the neuroendocrine stress response systems; and 3) 
dysregulation of neurotransmitters, e.g., increase in norepinephrine and glutamate, and decrease in 
serotonin [3–5]. 
1.2. Therapeutic Approaches for PTSD 
Pharmacotherapy approved for PTSD includes traditional antidepressant and anxiolytic 
medications, e.g., selective serotonin reuptake inhibitors (SSRIs), such as sertraline, paroxetine, 
fluoxetine; and serotonin and norepinephrine reuptake inhibitors (SNRIs), such as venlafaxine, which 
are considered as first-line treatments [5,6]. However, both SSRIs and SNRIs have only partial 
efficacy, with remission rates reported to range from 20% to 30%, as well as the onset of potential 
side-effects, mainly responsible for their early discontinuation and consequent poor efficacy [7]. 
Furthermore, second-generation antipsychotics (SGAs)—such as risperidone, quetiapine, and 
olanzapine—are suggested for managing symptoms for adults with a diagnosis of PTSD in a 
secondary care setting [6]. According to current guidelines, a trauma-focused psychotherapy (TFP), 
acting on cognitive restructuring is primarily recommended [8]. Finally, cognitive behavioral therapy 
(CBT) and eye movement desensitization and reprocessing (EMDR) have been shown to be effective 
in the treatment of PTSD and trauma-related disorders, by acting on the dysregulation of the learning 
process of aversive memories [6]. 
Other promising approaches for PTSD treatment are represented by molecules acting on 
different neurotransmitter circuits, e.g., 1) prazosin, which is an alpha 1 adrenergic antagonist, found 
to be effective in reducing symptoms of anxiety, hyperarousal and sleep disorders, which are typical 
of PTSD; 2) gamma amino butyric acid (GABA) agonists, such as pregabalin or gabapentin, which 
may be used in addition to an antidepressant therapy; 3) N-methyl d-aspartate (NMDA) receptor 
partial agonists such as D-cycloserine (DCS), which has been associated with a reduction in 
symptoms of anxiety, avoidance, and numbing, and has also demonstrated an ability to augment the 
learning process for extinction of conditioned fear responses in both animal and human models [3, 
9]. 
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1.3. Cannabis use in PTSD: A Coping Strategy? 
Research has demonstrated a strong link between trauma, PTSD, and substance use disorders 
(SUDs) in general, and particularly between cannabis use disorders and PTSD [10–13]. In fact, the 
pathophysiology of PTSD involves many of the structures and neurocircuitry identified as key 
components in the development and/or perpetuation of addictive processes, such as amygdala 
hyperactivity, chronic activation of brain stress systems, and increased corticotropin-releasing factor 
(CRF) during acute drug-withdrawal; and the medial prefrontal cortex and its connections to the 
nucleus accumbens and ventral pallidum involved in animal models of craving and drug-induced 
reinstatement [3]. It has been estimated that individuals with PTSD are 2–4 times more likely to have 
a SUD compared to individuals without PTSD [14]. An association between PTSD and SUD has been 
documented amongst US veterans [13,15,16], possibly due to shared etiological factors, but also in an 
attempt to act as a copying strategy for PTSD symptoms using substances, and specifically cannabis, 
as a self-medication [3,10,11,13,17]. In fact, cannabis has been consumed for to its calming and 
relaxing effects, in order to cope with symptoms of intrusions (like repeated and disturbing thoughts 
or dreams) and hyperarousal (anxiety, trouble sleeping, irritability) [1,7,18–22]. Between 2002 and 
2009, the diagnosis of a cannabis use disorder increased more than 50% (from 0.66% to 1.05%) 
amongst veterans [15], facilitated by users’ perception of safeness compared to 
psychopharmacological compounds and/or alcohol, both of which are reported to have undesired 
side-effects, ranging from loss of cognitive acuity and social withdrawal to anhedonia and decreased 
sex drive/libido, which cannabis usually did not cause [23].  
1.4. Cannabis, Cannabinoids, and Their Role in PTSD 
Marijuana is derived from the Sativa and Indica species of the Cannabis plants. It contains 
cannabinoids and several other classes of chemical compounds acting on the cannabinoid receptors. 
Specifically, Δ-9-tetrahydrocannabinol (THC) is a highly lipophilic alkaloid and is the primary 
psychoactive ingredient in marijuana, varying from 0.2% to 30% potency per plant and strain; whilst 
cannabidiol (CBD) is a non-psychotomimetic cannabinoid, with neuroprotective, analgesic, sedative 
antiemetic, antispasmodic, anti-inflammatory, and anxiolytic properties [7]. Both THC and CBD act 
on cannabinoid receptors, but, compared with THC, CBD shows a lower CB1 and CB2 receptor affinity 
and, being an inverse agonist at the human CB2 receptor, it shows anti-inflammatory effects as well 
[24]. The cannabinoid receptors are part of the endocannabinoid system (eCS) together with 
endogenous cannabinoids, such as N-arachidonoyl ethanolamine (anandamide) and 2-arachidonoyl 
glycerol (2-AG) [4,7]. CB1 receptors are mainly located in the brain and widely expressed in the 
prefrontal-limbic system, including areas such as the amygdala, hippocampus, and prefrontal cortex, 
while CB2 receptors are mainly expressed in peripheral immunological tissue, although their 
presence in the central nervous system has been also recently documented in regions such as the 
amygdala, hippocampus, striatum, substantia nigra and cortex. Both cannabinoid receptors cause 
different molecular events, resulting in a general inhibition of neurotransmitters release, such as 
glutamate, serotonin, noradrenaline, and dopamine, from pre-synaptic terminals of neurons where 
cannabinoid receptors are expressed [7,25]. In fact, the activation of circuitries and mechanisms 
involving CB receptors may intervene in some PTSD neurobiological pathways and symptoms, 
influencing its etiology and maintenance, e.g. : 
1) CB1 receptors are found in moderate to high levels throughout brain limbic structures, and 
have been shown to possess modulating properties on behaviors, including mood, stress, 
learning, and memory [4]: in fact, by activating the CB1 receptors in the amygdala, cannabis can 
potentially block the consolidation of aversive memories, fear, and anxiety; moreover, through 
stimulating CB1 receptors in the prefrontal cortex, cannabis may increase serotonin and, 
therefore, display antidepressant properties; finally, cannabis agonism on CB1 receptors in the 
hippocampus seems to improve neurogenesis, mood, and memory as well as causing decreases 
in hypervigilance, hyperarousal, and intrusive memories, effects which may contribute to the 
anxiolytic and antidepressant effects of cannabinoids [1,4,5,7]; conversely, animal studies have 
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shown that a reduction in the number of CB1 receptors may be associated with heightened 
indices of anxiety and depression, especially if the disorder persists [4]. 
2) Stimulation of the limbic and paralimbic areas might decrease amygdala and hypothalamus 
activity, regulating the hypothalamic–pituitary axis and cortisol response, and, therefore, 
decreasing hypervigilance and hyperarousal [1,5]. Conversely, a low eCB tone contributes to 
amygdala hyperactivation as well as anxiety and hyperarousal symptoms characteristic of 
PTSD, including sleep disturbances, memory and cognitive impairments, depression, and 
suicidality [14]. Interestingly, a difference in gender has been evidenced, with males showing a 
higher degree of endocannabinoids released in response to a stressor and stronger physiological 
effects to cannabis compared to women [4,26,27];  
3) Within the eCB system, reduced peripheral levels of anandamide, abnormal CB1 receptor-
mediated anandamide signaling and compensatory increase of CB1 receptor availability are 
implicated in PTSD etiology and degree of intrusive symptoms [1,4,7,11,27,28];  
4) Cannabinoid modulation exerts effects on memory processes through alteration of the brain-
derived neurotrophic factor (BDNF) concentrations in the hippocampus and the basolateral 
amygdala, as well as altering long-term potentiation in hippocampal neurons [27].  
1.5. Therapeutic use of Synthetic Cannabinoids in PTSD 
Several cannabinoid-acting compounds already approved to treat low appetite, nausea, 
vomiting, pain, and spasticity in cancer, AIDS, and multiple-sclerosis, have been furtherly developed 
due to the increasing interest in the role of the eCB system in fear, anxiety and stress, and in specific 
psychiatric conditions, such as PTSD [11]. Thus, a growing interest around the therapeutic use of 
cannabis and cannabinoids for the treatment of the PTSD symptoms [1] has emerged in recent years, 
with animal studies showing CBD may facilitate the disruption of fear memory consolidation, 
decrease the salience of ordinarily significant stimuli, or facilitate the extinction of fear memories [1], 
processes that are relevant to PTSD’s psychopathology [2,29,30]. The beneficial effects on anxiety 
depend on the cannabinoids’ agonism on the CB1 receptors, showing in animal models a biphasic 
dose-dependent effect, producing anxiolytic-like effects at low doses and producing an anxiogenic 
response at higher doses, possibly related to differences in sensitivities of CB1 receptors in neuronal 
systems [31]. Among all, Nabilone appeared to be the most explored synthetic cannabinoid in the 
treatment of PTSD. It is a synthetic cannabinoid agonist already approved by the Food and Drug 
Administration (FDA) for the treatment of chemotherapy-induced nausea and vomiting [32], but it 
has been also shown as promising for the treatment of PTSD-related insomnia and nightmares with 
increased sleep time and reduction of daytime flashbacks. Interestingly, it has also been proposed for 
harm reduction in cannabis dependence [28], with little evidence of development of tolerance and 
abuse recorded [33]. 
1.6. Aims of the Paper 
Current evidence regarding the therapeutic use of CBD and synthetic cannabinoids (SC) for 
PTSD in humans is minimal, with mixed results, ranging from improved symptoms to cautions 
concerning their efficacy. To date, no clinical trials evaluating their effectiveness in reducing 
symptoms of PTSD in humans have been completed.  
Therefore, we conducted a retrospective file review of adult patients with PTSD who were 
treated with CBD, nabilone, marijuana, or medical cannabis. This review firstly aims at providing an 
overview of PTSD and briefly describing the current knowledge available relating to cannabis, 
cannabinoids, and their use in PTSD treatment. Subsequently, a systematic approach including all 
the potential evidence examining cannabis and synthetic cannabinoids effectiveness in PTSD 
symptom reduction has been carried out. A review of all objectively selected, critically assessed, and 
reasonably synthesized evidence on experimental data, available up to May 2019, was undertaken.  
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2. Methods 
2.1. Search Sources and Strategies 
A systematic literature review was conducted following methods recommended by the 
Cochrane Collaboration [34], the process and results were documented in accordance with the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [35]. 
Literature searches were performed by using the following electronic databases (last update: May 
2019): MEDLINE, PubMed, Cochrane Library, and Web of Science online databases. We combined 
the search strategy of free text terms and exploded MESH headings for the topics of cannabis, 
synthetic cannabinoids, and PTSD as follows: (((cannabis[Title/Abstract]) OR (synthetic cannabinoids 
[Title/Abstract])) AND ((PTSD[Title/Abstract]) OR (Posttraumatic stress disorder[Title/Abstract]))). 
The strategy was first developed in MEDLINE and then adapted for use in the other databases. No 
restrictions by language were included in the search strategy. Moreover, no limitations on the year 
of publication were applied. Thus, studies published up to 31 May 2019 were included. Further 
studies were retrieved through hand-searches of reference listings of relevant articles and 
consultation with experts in the field.  
2.2. Study Selection 
We considered studies that included cannabis and/or synthetic cannabinoid treatment for PTSD. 
We examined all titles and abstracts and obtained full texts of potentially relevant papers. Working 
independently and in parallel, two reviewers (LO and SC) read the papers and determined whether 
they met inclusion criteria. Duplicate publications were excluded. All English-language articles 
identified by the data sources, reporting original data related to cannabis and/or cannabinoids in 
PTSD were evaluated in the present review. All experimental and observational study designs were 
included apart from case reports. Randomized, controlled clinical trials involving humans were 
prioritized whilst preclinical/animal studies were excluded in the present systematic review. 
Narrative and systematic reviews, letters to the editor and book chapters were excluded as well for 
the specific aim of the systematic review but considered useful for the background of the research. 
Furthermore, only studies recruiting adult subjects were considered. 
2.3. Data Extraction and Management 
LO and SC independently extracted the data on participant characteristics, intervention details 
and outcomes measures. Disagreements were resolved by discussion and consensus with a third 
member of the team (GDP). Data were collected using a data extraction spreadsheet developed 
specifically for this study.  
2.4. Characteristics of Included Studies 
From 123 potentially relevant records from the search of databases and additional sources, 36 
were excluded on the basis of title or abstract (Figure 1). The remaining 87 studies were retrieved for 
more detailed evaluation, of which 7 were excluded because of duplication, 66 were excluded as not 
pertinent to inclusion criteria or editorial, reviews or case-reports, whilst 2 were excluded due to 
being without full text. Overall, 12 studies met the inclusion criteria, of these: 3 about nabilone, 3 
about THC, 1 about CBD, and 5 about medical cannabis were thoroughly analyzed. The main 
characteristics of the 12 studies are reported in Table 1. 
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Table 1. Summary of retrieved papers 
Study 
(author(s), 
year of 
publication
) 
Sample 
Characteristic
s 
Cannabinoi
d or 
Cannabis-
Based 
Medicine 
Implicated 
Control 
Group 
(if any) 
Dose (s) ROA 
Outcome
s 
Measure
s Used 
Main Findings 
Fraser 
(2009) [32] 
47 patients 
with treatment-
resistant PTSD 
Nabilone None 
0.5 mg 
titrated up 
to a max 
of 4 mg 
daily 
OS 1 h 
prior to 
bedtime 
Nightmar
e 
presence 
and 
intensity; 
hours of 
sleep 
Reduction in 
nightmare 
intensity, 
subjective 
improvement in 
sleep time, 
quality of sleep, 
and reduction of 
daytime 
flashbacks and 
night sweats. 
 
Bonn-
Miller et al. 
(2014a) 
[13] 
170 patients at 
a medical 
cannabis 
dispensary in 
California 
CBD + THC 
Pts 
without 
PTSD 
n.d. n.d. 
PCL-C 
CMMQ 
MSHQ 
AUDIT 
IDAS 
Improvement of 
PTSD-related 
sleep 
disturbances but 
only 8/40 of 
PTSD subjects 
reported a 
reduction in 
PTSD 
symptoms. 
 
Bonn-
Miller et al. 
(2014b) 
[35] 
217 patients at 
a medical 
cannabis 
dispensary in 
California 
CBD + THC 
Pts 
without 
PTSD 
n.d. n.d. n.d. 
Reduction of 
stress, anxiety, 
depression, and 
PTSD 
symptomatolog
y. 
 
Cameron et 
al. (2014) 
[27] 
104 male 
inmates with 
serious mental 
illness 
Nabilone None 
Mean 
initial 
dose: 1.4 
mg daily 
(0.5-2 
mg) 
Mean 
final 
dose: 5 
mg daily 
(0.5-6 
mg) 
n.d. PCL-C GAF 
Significant 
improvement in 
PTSD-
associated 
insomnia, 
nightmares, 
PTSD 
symptoms. 
 
Earleywine 
and Bolles 
(2014) [16] 
650 combat-
exposed male 
veterans 
THC None unknown 
Smoked, 
at least 
once per 
week 
PCL-M 
CES 
Significant 
expectations of 
cannabis-
induced relief 
from PTSD 
symptomatolog
y, particularly 
for intrusion, 
hyperarousal, 
then avoidance, 
and numbing. 
 
Greer et al., 
(2014) [36] 
80 PTSD 
patients CBD+THC None 
Unknown 
proportio
n 
Smoked CAPS 
PTSD 
symptoms 
reduction. 
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Roitman et 
al. (2014) 
[39] 
10 PTSD 
outpatients 
from Israel 
THC None 
2x2.5 mg 
daily 
titrated to 
5 mg x 2 
daily 
OS 1 h 
after 
waking 
up and 2 
h prior to 
bed 
PSQI 
NFQ 
NES 
Reduction in 
nightmares and 
improvement in 
sleep quality. 
 
Jetly et al. 
(2015) [41] 
10 male 
military 
personnel with 
PTSD 
Nabilone Placebo 
0.5 mg 
titrated to 
3 mg 
OS 1 h 
prior to 
bed 
CAPS 
sleep 
items 
PTSD 
dream 
rating 
scale 
Sleep 
diary 
CGI-C 
WBQ 
 
Reduction in 
nightmares. 
Wilkinson 
et al. (2015) 
[37] 
2276 PTSD 
veterans 
admitted to 
intensive 
PTSD 
treatment 
programs and 
divided into a) 
never cannabis 
users; b) 
cannabis users 
stoppers; c) 
continuing 
cannabis users; 
d) cannabis use 
starters 
CBD+THC Comparing groups n.d. n.d. 
ASI 
MISS for 
PTSD 
Starting 
cannabis use 
worsened PTSD 
symptoms. 
Stopping 
cannabis use 
improved PTSD 
symptoms. 
At follow-up, 
stoppers and 
never cannabis 
users had lower 
levels of PTSD 
symptoms, and 
starters had the 
highest levels of 
violent 
behavior. 
 
Johnson et 
al. (2016) 
[40] 
700 veterans 
enrolled in the 
primary care 
mental health 
integration 
program 
THC Placebo n.d. Smoked 
TLFB 
ASSIST 
PCL-
CPHQ-9 
PQSIA 
BOMC 
No association 
between 
cannabis use and 
less severe 
PTSD 
symptomatolog
y. 
Tull et al. 
(2016) [38] 
202 subjects 
with and 
without PTSD 
with a co-
occurring 
stimulant, 
cocaine or 
alcohol use 
disorder 
admitted to a 
SUD treatment 
facility 
CBD + THC Placebo n.d. n.d. 
SCID-I 
CAPS 
MINI 
PANAS 
DUQ 
Current PTSD 
was associated 
with greater 
subjective 
emotional 
reactivity to the 
trauma script 
only in subjects 
without 
cannabis use. 
 
Cannabis users 
(with and 
without PTSD) 
reported less 
subjective 
emotional 
reactivity than 
participants with 
PTSD but 
without 
cannabis use. 
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Elms et al. 
(2019) [24] 
11 PTSD 
outpatients CBD None 
Flexible 
for 8 
weeks  
OS 
capsule 
or liquid 
spray 
once or 
twice per 
day based 
on 
severity 
of 
symptom
s 
 
PCL-5 
Decreased 
PTSD symptom 
severity at 8 
weeks from 
baseline. 
Abbreviations: ROA: route of administration; pts: patients; PTSD: post-traumatic stress disorder; wks: 
weeks; CBD: cannabidiol; OS: oral; PCL-C: PTSD Checklist-Civilian Version; PCL-5: patient-
completed PTSD Checklist for the DSM-5; CMMQ: Comprehensive Marijuana Motives 
Questionnaire; MSHQ: Marijuana Smoking History Questionnaire; AUDIT: Alcohol Use Disorders 
Identification Test; IDAS: Inventory of Depression and Anxiety Scale; GAF: Global Assessment of 
Functioning; PCL-M: Post-Traumatic Stress Disorder Checklist-Military Version; CES: Combat 
Exposure Scale; PSQI: Pittsburgh Sleep Quality Index; NFQ: Nightmare Frequency Questionnaire-
Revised; NES: Nightmare effects survey; CAPS: Clinical Administered PTSD Scale; CGI-C: Clinical 
Global Impression of Change; WBQ: General Well Being Questionnaire; n.d.: not documented; TLFB: 
Alcohol Timeline Followback; ASSIST: Alcohol, Smoking, and Substance Involvement Screening Test; 
PHQ-9: Patient Health Questionnaire; PQSIA: Paykel questionnaire for suicidal ideations and 
attempts; BOMC: Blessed Orientation-Memory-Concentration Test; SCID-I: Structured Clinical 
Interview for DSM-IV Axis; ASI: Addiction Severity Index; MISS: Mississippi Scale for PTSD; I 
Disorders; MINI: Mini International Neuropsychiatric Interview, version 6.0; PANAS: Positive and 
Negative Affect Scales; DUQ: Drug Use Questionnaire. 
3. Results 
3.1. Medical Cannabis 
A cross-sectional study of 170 medical cannabis users in California, estimated around 19% of 
participants with a PTSD diagnosis. Cannabis users with high PTSD scores were more likely to use 
cannabis to improve sleep and as coping strategy, even though only a minority (8/40) reported a 
significant reduction in PTSD symptomatology [14]. Conversely, another cross-sectional study from 
the same group recruited 217 medical cannabis users in California, reporting a reduction of 
hyperarousal symptoms, such as stress (24%) and anxiety (20%); depressive symptoms (10%); and in 
general of PTSD symptomatology (4%) amongst PTSD participants, particularly those with greater 
levels of traumatic intrusions and lower levels of well-being [36]. This result was echoed by a study 
that retrospectively evaluated PTSD symptoms described by patients following the New Mexico 
Medical Cannabis Program from 2009 to 2011, reporting a reduction of > 75% in PTSD 
symptomatology in patients using cannabis compared to when they were not [37]. Conversely, a 
longitudinal, observational study evaluating the association between cannabis use and PTSD 
symptom severity recruited 2,276 PTSD participants admitted to specialized veterans’ treatment 
programs, classified into four groups according to their cannabis use: those without cannabis use at 
admission or after discharge (“never used”); those who used cannabis at admission but not after 
discharge (“stoppers”); those who used at admission and after discharge (“continuing users”) and 
those using cannabis after discharge but not at admission (“starters”) [38], and interestingly, cannabis 
use was significantly associated with worse outcomes in PTSD symptom severity, violent behavior, 
and measures of alcohol and drug use. At follow-up, stoppers and never users had the lowest levels 
of PTSD symptomatology whilst starters showed the highest levels of violent behavior [38]. Finally, 
analyzing 202 patients coming from a SUD inpatients treatment facility with and without PTSD 
diagnosis [39], current PTSD was associated with greater subjective emotional reactivity to the 
trauma narrative only amongst subjects without cannabis dependence; amongst those with cannabis 
dependence, subjective emotional reactivity did not differ as a function of PTSD status. Cannabis-
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dependent participants (with and without PTSD) reported less subjective emotional reactivity than 
participants with PTSD but without cannabis dependence. No significant differences were found in 
cortisol reactivity [39].  
3.2. THC  
A large sample of combat-exposed U.S. veterans who used marijuana at least once per week 
reported significant expectations of cannabis-induced relief from PTSD symptomatology, 
particularly for relief from intrusive symptoms (e.g., repeated, disturbing thoughts or dreams) 
followed by hyperarousal (e.g., trouble sleeping and irritability), avoidance (e.g., thoughts or 
activities related to trauma), and numbing (e.g., feeling distant, emotionally numb) [17]. These data 
appeared to be consistent with the ‘self-medication’ hypothesis of cannabis use for PTSD symptoms. 
An open-label pilot study carried out on 10 outpatients with chronic PTSD, on stable medication, 
found that add-on 5 mg of THC twice a day may lead to an improvement in sleep quality and a 
reduced frequency in PTSD-related nightmares, even though it may cause some mild adverse effects 
(e.g., headache, dizziness, and dry mouth) [40]. A case-control, cross-sectional study, evaluating the 
association between cannabis use and PTSD symptomatology, reported no significant differences 
between cases and controls in mean PTSD CheckList (PCL) scores and no association between PTSD 
scores and frequency of cannabis use. The findings did not support the theory that cannabis would 
be associated with less severe PTSD symptomatology [41]. 
3.3. CBD 
A retrospective open-label study examining CBD oral administration in flexible doses on PTSD 
symptomatology for 8 weeks reported a significant reduction in PTSD severity and intensity. CBD 
was well tolerated, and no patients discontinued treatment due to side-effects [25]. 
3.4. Nabilone 
Fraser [33] reported a study examining the effect of nabilone in managing PTSD-related 
nightmares. Nabilone treatment significantly reduced the presence and intensity of nightmares as 
well as increased hours of sleep per night of PTSD subjects. Discontinuation was attempted every 6 
months. Whilst four patients had a complete recovery after 4–12 months, the rest experienced 
recurrence of nightmares following nabilone withdrawal, thus necessitating resumption of treatment. 
A retrospective study recruiting 104 male inmates with serious mental illness showed that nabilone 
prescription significantly reduces polypharmacy risk and significantly improves PTSD-associated 
insomnia, nightmares, and PTSD symptoms [28]. A double-blind, placebo-controlled cross-over trial 
carried out on 29 Canadian male military service members with documented PTSD received double-
blind treatment with 0.5 mg of nabilone or placebo and were followed until 7 weeks and then, 
following a 2-week wash-out period, were titrated with the other study treatment and followed for 
an additional 7 weeks, in order to evaluate the potential use of nabilone for the treatment of PTSD-
related nightmares [42]. The clinician-administered PTSD scale recurring and distressing dream 
scores were significantly reduced in the nabilone group compared to placebo [42]. 
4. Discussion 
A significant overlap has been demonstrated between PTSD and SUD [13] in several 
epidemiological studies which estimate that individuals with PTSD are 2–4 times more likely to have 
a SUD compared to non-PTSD subjects [43,44]. PTSD subjects with concomitant SUD reported being 
more likely to take substances to “self-medicate”, meant to mitigate distressing PTSD symptoms [45–
47]. Particularly, expectations for anxiety and reduced tension represented the most commonly 
reported motivations for using cannabis and cannabinoid compounds amongst PTSD subjects [48], 
lifetime cannabis use being 3.3 times more likely in PTSD diagnosis [48]. Given the interactions 
between cannabinoids and specific neurotransmitters (e.g., GABA, serotonin, glutamate, and 
dopamine), it has been proposed that cannabis may potentially confer some degree of medical benefit 
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to PTSD. In fact, PTSD subjects may use cannabis and cannabis-related compounds mainly due to 
their anxiolytic, sedative, hypnotic, dream recall suppressor, and antipsychotic activities [1,14,17,25, 
28,32,36,37,39]. Interestingly, military veterans are increasingly using cannabinoids for relief of PTSD-
induced nightmares [14,28,33,40,42]. Nonetheless, nightmares associated with PTSD are often a 
residual symptom that remains difficult to treat despite improvements in other domains [9].  
Preclinical research has shown promising findings for CBD as an enhancer of fear extinction and 
therapeutic consolidation of emotional memories [27,30,49]. Current evidence regarding the use of 
CBD for PTSD in humans and its relevance for intrusive memories and memory consolidation in 
PTSD is minimal and controversial [25]. A case-report reported that oral CBD administration (12–37 
mg daily) was associated with reduced anxiety and sleep symptoms related to PTSD in a 10-year-old 
sexually-abused patient [50]. CBD has been shown to cause a decreased response to and increased 
extinction of aversive memories, improve performance on inhibitory avoidance tasks, as well as 
produce an anxiolytic effect in PTSD patients [25,51–53]. Preclinical and clinical studies on nabilone 
show promising findings, mainly in reducing nightmares and sleep disorders related to PTSD 
[27,28,33,42,53,54]. Conversely, no clinical evidence exists so far for dronabinol. 
Despite improvements in PTSD symptomatology, there are demonstrable adverse health risks 
associated with cannabis use, as chronic recreational use is associated with dependence and THC-
related cognition dysfunction and risk of psychosis [31,55]. Similarly, chronic use of marijuana is 
associated with global cortical downregulation of CB1 receptor availability, as well as across regions 
such as the temporal lobe, nucleus accumbens, and cingulate cortex, resulting in reduced endogenous 
cannabinoid functioning, reflecting tolerance and dependence effects [27]. Moreover, the anxiolytic 
effects of cannabis depend upon the neurobiological interplay or ratio metric relationship between 
the two major phyto-cannabinoids found in the cannabis plant, THC and CBD [11,56]. Apart from 
beneficial effects on anxiety, hyperarousal, and trauma-related symptoms described, synthetic 
cannabinoids have been reported to induce anxiety in healthy subjects and increase symptom 
severity in PTSD patients [38,41], effects which have been attributed to a downregulation of the eCB 
signaling system, resulting in tolerance to the drug’s anti-anxiety effects and, in some cases, an 
unmasking of pro-anxiety properties [3]. Moreover, some toxic effects, including respiratory 
depression, hyperthermia, acute cerebral ischemia, and seizures have been related to synthetic 
cannabinoids [32]. Finally, abrupt discontinuation of daily synthetic cannabinoids use can precipitate 
withdrawal syndrome three or four days after stoppage characterized by waxing and waning 
behavioral, mood, and physical symptoms such weakness, sweating, restlessness, dysphoria, 
sleeping problems, anxiety, craving, and diaphoresis [32]. 
Furthermore, several limitations should be considered when interpreting the findings coming 
from the present systematic review. First, studies examined here show an extreme heterogeneity of 
methodological strategies (in terms of sample features, sample size, pretreatment cannabis users or 
not, concomitant other substances abused, type of cannabinoid taken, variable and/or unspecified 
dosages and route of administration of cannabinoids used by PTSD patients, etc.). Second, there are, 
so far, no randomized, controlled, clinical trials with active marijuana use. Furthermore, for ethical 
reasons it is not possible to carry out a clinical trial using medical cannabis in all countries, hence, 
most findings presented here come only from countries in which medical cannabis is allowed and/or 
performing trials using THC and/or other synthetic cannabinoids is permitted.  
Increasing our understanding of appropriate cannabinoids dosing levels must be further 
established before definitive clinical trials can begin, and this may increasingly reflect a move away 
from whole plant products due to difficulty in regulating levels of the active compounds in this form 
of the product. Furthermore, the eCS acts in different ways even in the same disease states, meaning 
that for many conditions the direction in which the system should be modulated is unclear and 
upstream options for treatment should also be researched [27]. These limitations notwithstanding, 
our findings highlight the importance of carrying out further research, more specifically focusing on 
the role of the eCS in other systems relevant to PTSD, such as the dopaminergic and serotonergic 
pathways.  
  
Medicina 2019, 55, 525 11 of 14 
 
5. Conclusions 
Given the recent move towards understanding shared mechanisms between psychiatric fields, 
such as between PTSD and psychotic illnesses, there is an increasing need to deepen knowledge of 
the role of specific molecular mediators between these illnesses which may explain their similarities 
and overlapping routes, including in the field of SUD. Nowadays, the eCS represents a system where 
shared mechanisms may be identified. Hence, exploring its variable molecular interactions in anxiety 
and PTSD may benefit and improve knowledge as well in other psychiatric fields. Finally, the efficacy 
and safety/tolerability of both natural and recently emergent synthetic cannabinoids in the treatment 
of other psychiatric disorders should be better investigated, including PTSD. Randomized clinical 
trials and experimental studies should be furtherly encouraged due to the limited clinical evidence 
so far published. 
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